Gregory M. Weinhoff

Gregory M. Weinhoff (finance chief) discloses dealings in Centessa Pharmaceuticals plc to SEC (Form 4). In total, 48 filings cover trades dated from 2 June 2021 to 24 June 2026.

The open-market side counts 1 purchase for €164k alongside 20 sales for €5.2M. The net balance comes to €5.0M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 17 share grants and 9 option exercises. 2026 to date brings no purchases and 3 sales.

On 24 June 2026 came the latest disclosure, a transaction in Centessa Pharmaceuticals plc. The most recent open-market purchase was published on 4 June 2021, 1,968 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.